FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3036638795> ?p ?o ?g. }

• W3036638795 abstract "Abstract Introduction People living with HIV (PLHIV) have an elevated risk of atherosclerotic cardiovascular disease (CVD) compared to their HIV‐negative peers. Expanding statin use may help alleviate this burden. However, the choice of statin in the context of antiretroviral therapy is challenging. Pravastatin and pitavastatin improve cholesterol levels in PLHIV without interacting substantially with antiretroviral therapy. They are also more expensive than most statins. We evaluated the cost‐effectiveness of pravastatin and pitavastatin for the primary prevention of CVD among PLHIV in Thailand who are not currently using lipid‐lowering therapy. Methods We developed a discrete‐state microsimulation model that randomly selected (with replacement) individuals from the TREAT Asia HIV Observational Database cohort who were aged 40 to 75 years, receiving antiretroviral therapy in Thailand, and not using lipid‐lowering therapy. The model simulated each individual’s probability of experiencing CVD. We evaluated: (1) treating no one with statins; (2) treating everyone with pravastatin 20mg/day (drug cost 7568 Thai Baht ($US243)/year) and (3) treating everyone with pitavastatin 2 mg/day (drug cost 8182 Baht ($US263)/year). Direct medical costs and quality‐adjusted life‐years (QALYs) were assigned in annual cycles over a 20‐year time horizon and discounted at 3% per year. We assumed the Thai healthcare sector perspective. Results Pravastatin was estimated to be less effective and less cost‐effective than pitavastatin and was therefore dominated (extended) by pitavastatin. Patients receiving pitavastatin accumulated 0.042 additional QALYs compared with those not using a statin, at an extra cost of 96,442 Baht ($US3095), giving an incremental cost‐effectiveness ratio of 2,300,000 Baht ($US73,812)/QALY gained. These findings were sensitive to statin costs and statin efficacy, pill burden, and targeting of PLHIV based on CVD risk. At a willingness‐to‐pay threshold of 160,000 Baht ($US5135)/QALY gained, we estimated that pravastatin would become cost‐effective at an annual cost of 415 Baht ($US13.30)/year and pitavastatin would become cost‐effective at an annual cost of 600 Baht ($US19.30)/year. Conclusions Neither pravastatin nor pitavastatin were projected to be cost‐effective for the primary prevention of CVD among PLHIV in Thailand who are not currently using lipid‐lowering therapy. We do not recommend expanding current use of these drugs among PLHIV in Thailand without substantial price reduction." @default.
• W3036638795 created "2020-06-25" @default.
• W3036638795 creator A5004174170 @default.
• W3036638795 creator A5012209235 @default.
• W3036638795 creator A5020905737 @default.
• W3036638795 creator A5028932019 @default.
• W3036638795 creator A5038605024 @default.
• W3036638795 creator A5052308665 @default.
• W3036638795 creator A5054279994 @default.
• W3036638795 creator A5059390735 @default.
• W3036638795 creator A5064903621 @default.
• W3036638795 creator A5067872651 @default.
• W3036638795 creator A5071540404 @default.
• W3036638795 creator A5079993549 @default.
• W3036638795 creator A5086641466 @default.
• W3036638795 date "2020-06-01" @default.
• W3036638795 modified "2023-09-30" @default.
• W3036638795 title "Statins for atherosclerotic cardiovascular disease prevention in people living with HIV in Thailand: a cost‐effectiveness analysis" @default.
• W3036638795 cites W1512865803 @default.
• W3036638795 cites W1522504371 @default.
• W3036638795 cites W1562761056 @default.
• W3036638795 cites W1749910810 @default.
• W3036638795 cites W1877489180 @default.
• W3036638795 cites W1981272315 @default.
• W3036638795 cites W2000650108 @default.
• W3036638795 cites W2003421870 @default.
• W3036638795 cites W2008231328 @default.
• W3036638795 cites W2012103753 @default.
• W3036638795 cites W2033024867 @default.
• W3036638795 cites W2037720442 @default.
• W3036638795 cites W2044645845 @default.
• W3036638795 cites W2056238830 @default.
• W3036638795 cites W2057578063 @default.
• W3036638795 cites W2057851884 @default.
• W3036638795 cites W2068048882 @default.
• W3036638795 cites W2077185492 @default.
• W3036638795 cites W2098473115 @default.
• W3036638795 cites W2099395511 @default.
• W3036638795 cites W2102777394 @default.
• W3036638795 cites W2115169717 @default.
• W3036638795 cites W2118184073 @default.
• W3036638795 cites W2119150423 @default.
• W3036638795 cites W2120972109 @default.
• W3036638795 cites W2135594909 @default.
• W3036638795 cites W2137366606 @default.
• W3036638795 cites W2141078353 @default.
• W3036638795 cites W2145963739 @default.
• W3036638795 cites W2150995053 @default.
• W3036638795 cites W2154292937 @default.
• W3036638795 cites W2160970334 @default.
• W3036638795 cites W2162249283 @default.
• W3036638795 cites W2166805130 @default.
• W3036638795 cites W2180281498 @default.
• W3036638795 cites W2304461253 @default.
• W3036638795 cites W2317619427 @default.
• W3036638795 cites W2518488979 @default.
• W3036638795 cites W2519603001 @default.
• W3036638795 cites W2520174553 @default.
• W3036638795 cites W2562637560 @default.
• W3036638795 cites W2578958358 @default.
• W3036638795 cites W2580792129 @default.
• W3036638795 cites W2582598608 @default.
• W3036638795 cites W2591049662 @default.
• W3036638795 cites W2594208926 @default.
• W3036638795 cites W2596404483 @default.
• W3036638795 cites W2607348111 @default.
• W3036638795 cites W2729683435 @default.
• W3036638795 cites W2736607134 @default.
• W3036638795 cites W2737419352 @default.
• W3036638795 cites W2761345412 @default.
• W3036638795 cites W2792191482 @default.
• W3036638795 cites W2793444448 @default.
• W3036638795 cites W2896782950 @default.
• W3036638795 cites W2909645770 @default.
• W3036638795 cites W2912654919 @default.
• W3036638795 cites W2913548118 @default.
• W3036638795 cites W2948531466 @default.
• W3036638795 cites W3012723983 @default.
• W3036638795 cites W3025713364 @default.
• W3036638795 cites W4236673002 @default.
• W3036638795 cites W4313635028 @default.
• W3036638795 doi "https://doi.org/10.1002/jia2.25494" @default.
• W3036638795 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7305414" @default.
• W3036638795 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32562359" @default.
• W3036638795 hasPublicationYear "2020" @default.
• W3036638795 type Work @default.
• W3036638795 sameAs 3036638795 @default.
• W3036638795 citedByCount "2" @default.
• W3036638795 countsByYear W30366387952020 @default.
• W3036638795 countsByYear W30366387952021 @default.
• W3036638795 crossrefType "journal-article" @default.
• W3036638795 hasAuthorship W3036638795A5004174170 @default.
• W3036638795 hasAuthorship W3036638795A5012209235 @default.
• W3036638795 hasAuthorship W3036638795A5020905737 @default.
• W3036638795 hasAuthorship W3036638795A5028932019 @default.
• W3036638795 hasAuthorship W3036638795A5038605024 @default.
• W3036638795 hasAuthorship W3036638795A5052308665 @default.
• W3036638795 hasAuthorship W3036638795A5054279994 @default.
• W3036638795 hasAuthorship W3036638795A5059390735 @default.
• W3036638795 hasAuthorship W3036638795A5064903621 @default.

• next